Amir Sherif

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Endovascular approach to treating secondary arterioureteral fistula
    A Sherif
    Department of Urology, Uppsala Akademiska Sjukhus, Sweden
    Scand J Urol Nephrol 36:80-2. 2002
  2. ncbi Treatment of muscle-invasive bladder cancer
    Amir Sherif
    Karolinska University Hospital, Department of Urology, 171 76 Stockholm, Sweden
    Expert Rev Anticancer Ther 7:1279-83. 2007
  3. ncbi Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies
    Amir Sherif
    Department of Urology, Akademiska University Hospital, SE 751 85 Uppsala, Sweden
    Eur Urol 45:297-303. 2004
  4. ncbi Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer
    Amir Sherif
    Department of Urology, Uppsala University Hospital, Uppsala, Sweden
    Eur Urol 50:83-91. 2006
  5. ncbi Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2
    Amir Sherif
    Department of Urology, Akademiska University Hospital, Uppsala, Sweden
    Scand J Urol Nephrol 36:419-25. 2002
  6. ncbi Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept
    Amir Sherif
    Department of Urology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Eur Urol 58:105-11. 2010
  7. ncbi Detection of immune responses against urinary bladder cancer in sentinel lymph nodes
    Per Marits
    Department of Internal Medicine, Uppsala University Hospital, S-751 85 Uppsala, Sweden
    Eur Urol 49:59-70. 2006
  8. ncbi Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007

Detail Information

Publications10

  1. ncbi Endovascular approach to treating secondary arterioureteral fistula
    A Sherif
    Department of Urology, Uppsala Akademiska Sjukhus, Sweden
    Scand J Urol Nephrol 36:80-2. 2002
    ..Both patients presented with the clinical sign of intermittent gross hematuria. Both patients were successfully treated by endovascular intervention using graft covered stent...
  2. ncbi Treatment of muscle-invasive bladder cancer
    Amir Sherif
    Karolinska University Hospital, Department of Urology, 171 76 Stockholm, Sweden
    Expert Rev Anticancer Ther 7:1279-83. 2007
    ....
  3. ncbi Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies
    Amir Sherif
    Department of Urology, Akademiska University Hospital, SE 751 85 Uppsala, Sweden
    Eur Urol 45:297-303. 2004
    ..We analyzed overall survival in all patients and in prespecified subgroups defined by preoperative T-stage, gender and age...
  4. ncbi Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer
    Amir Sherif
    Department of Urology, Uppsala University Hospital, Uppsala, Sweden
    Eur Urol 50:83-91. 2006
    ..To explore the feasibility of performing lymphoscintigraphy combined with computed tomography (CT) for preoperative detection of sentinel lymph nodes in patients with invasive bladder cancer...
  5. ncbi Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2
    Amir Sherif
    Department of Urology, Akademiska University Hospital, Uppsala, Sweden
    Scand J Urol Nephrol 36:419-25. 2002
    ..CONCLUSIONS: The chemotherapy regimen was well tolerated. Despite substantial downstaging no statistically significant survival benefit with the neoadjuvant therapy could be seen after 5 years of follow-up...
  6. ncbi Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept
    Amir Sherif
    Department of Urology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    Eur Urol 58:105-11. 2010
    ..Metinel nodes (MNs) drain secondarily from metastatic tumors and also possess tumor-reactive lymphocytes, which might be a source for adoptive T-cell immunotherapy...
  7. ncbi Detection of immune responses against urinary bladder cancer in sentinel lymph nodes
    Per Marits
    Department of Internal Medicine, Uppsala University Hospital, S-751 85 Uppsala, Sweden
    Eur Urol 49:59-70. 2006
    ..These cells display immunologic function upon restimulation in vitro, and provide a promising source for expansion and subsequent adoptive T cell immunotherapy...
  8. ncbi Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007
    ....